275 S Bryn Mawr Ave, F18,
55 articles with Bristol-Myers Squibb
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases
Global, Multi-Program Collaboration Now Includes Anokion’s Novel Product Candidates for Celiac Disease, in addition to Multiple Sclerosis and the Platform CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb, focused
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J., & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Application (BLA) for idecabtagene vicle
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius and add their TGF-beta program to
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’s
Dr. Reddy’s licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date previously granted to Natco Dr. Reddy’s also licensed to sell generic lenalidomide in the U.S. without volume limitation beginning on January 31, 2026 The earliest licensed entry of any generic lenalidomide in the U.S. continues to be March 2022, based on settlements reached NEW YORK--( BUSIN
Obsidian Therapeutics , Inc. , a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the i
European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma
European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma Opdivo plus Yervoy would potentially be the first immunotherapy option for the first-line treatment of this cancer with high unmet needs Application based on positive results from pivotal Phase 3 CheckMate -743 trial PRINCETON, N.J.--( B
Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases, today announced that they have entered into a definitive agreement under w
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection Second tumor, in addition to melanoma, where Opdivo ha
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET™ immunotherapy drug candidate from Dr
Stand Up To Cancer® announces new research and education effort focused on improving health equity for underserved lung cancer patients
Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.
ReviveMed is proud to announce that they are pursuing an evaluation study with Bristol Myers Squibb (NYSE: BMY). This study will leverage ReviveMed’s artificial intelligence (AI) platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer. “We are very excited about this opportunity to work alongside industry leaders on the Bristol Myers Squibb team,” said Dr. Leila
Lupus Research Alliance Announces Nine Recipients of New Award in Partnership with Bristol Myers Squibb
The Lupus Research Alliance (LRA) is pleased to announce the first recipients of the inaugural LRA-BMS Accelerator Award*, a collaborative project with sponsoring partner Bristol Myers Squibb. The Award provides a collective total of $3,000,000 to support nine cutting-edge lupus research projects over two years that focus on understanding t
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for ZEPOSIA® (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. ZEPOSIA is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).
X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb. T
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb
Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.S.) and European Union (EU) for the ongoing review of its applications for an indication in metastatic first-line non-small cell lung cancer with Opdivo (nivolumab) plus low-dose Yervoy
Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise.
Trio Joins Bristol-Myers Squibb to Inspire People to Show How They Harness Their Unique Inner Power in the Fight Against Cancer
Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018
Nektar Therapeutics and Bristol-Myers Squibb announced presentation of preliminary data from the ongoing PIVOT Phase 1/2 Study.
Doctors surveyed for Taking the Pulse® U.S., the longest-running U.S. study of online physician attitudes and multichannel behaviors, rated Bristol-Myers Squibb and Biogen as the most "trusted partners" based on recent digital interactions.
Strengthens Real-World Data Capabilities in Oncology Research at BMS